ProBioGen AG and Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, have signed a Service Agreement for the cell line development, process development and GMP manufacture of Immunogenesis’ lead immuno-oncology candidate in 1,000 L bioreactor scale. Immunogenesis’ first-in-class monoclonal antibody candidate has two different specificities resulting from R&D work at the MD Anderson Cancer Center, University of Texas. Using its CHO.RiGHT expression platform for high-titer cel...